Evinacumab Lowers LDL-C Levels in Familial Hypercholesterolemia
According to a double-blind, placebo-controlled, phase III clinical study published in the August 20, 2020 issue of the New England of Journal of Medicine, evinacumab, a monoclonal antibody against angiopoietin-like 3, has the potential to diminish low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia. Read more.

Treprostinil Awarded sNDA for Pulmonary HTN With Interstitial Lung Disease 
On August 17, 2020, in a press release, it was announced that the FDA accepted for review the supplemental New Drug Application (sNDA) for treprostinil (Tyvaso) inhalation solution, a prostacyclin vasodilator, for the treatment of pulmonary hypertension (HTN) associated with interstitial lung disease. The manufacturer hopes that the FDA will complete its review by April 2021. Read more.

P2Y12 Inhibitor Use Linked With Reduced Microcirculatory Resistance
In a recent retrospective study published in the Journal of Interventional Cardiology, results indicate that loading of third-generation P2Y12 inhibitors before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction was linked with a decrease in the index of microcirculatory resistance. Read more.